4 results about "Piroxicam" patented technology

This invention discloses a piroxicam-containing solid dispersion and its preparation method. The piroxicam-containing solid dispersion of this invention constructs drug-carrier and carrier-carrier interactions from different dimensions, synergistically promoting the solubilizing ability of each carrier for the drug, improving the stability of the amorphous solid dispersion, and significantly increasing its apparent solubility. Furthermore, numerous in vivo experiments demonstrate that the quaternary system of the solid dispersion of this invention improves the bioavailability of piroxicam. The preparation technology of the piroxicam solid dispersion provided by this invention is simple, highly reproducible, and has good prospects for industrial production.

The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.

This invention discloses a block-shaped piroxicam crystal and its direct compression formulation method, relating to the field of pharmaceutical formulation technology. The block-shaped piroxicam crystal is prepared according to the following steps: crude piroxicam is dissolved in a solvent, an organic acid and polyvinylpyrrolidone are added, the mixture is cooled and crystallized, and then filtered, washed, and dried to obtain block-shaped piroxicam crystals. The solvent is acetonitrile or ethyl acetate; the organic acid is glutaric acid or citric acid. The active pharmaceutical ingredient powder prepared by this invention has an angle of repose ≤35°, good flowability, which ensures smooth material transportation, mixing, and tableting processes, resulting in small tablet weight differences and high content uniformity. The finished tablet has a hardness ≥90 kgf, high mechanical strength, and a friability ≤0.02%, exhibiting extremely strong wear and breakage resistance, making it less prone to damage during production, packaging, and transportation. The 15-minute dissolution rate ≥50% balances formability and dissolution, facilitating rapid drug release and improving in vivo bioavailability.

The utility model relates to the technical field of piroxicam methylate, in particular to a piroxicam methylate crude product refining device which comprises a base, a crystallizing tank fixedly mounted at the top of the base through a plurality of supporting legs, a refrigerating mechanism mounted on the outer side surface of the crystallizing tank, a top cover mounted at the top of the crystallizing tank, and a second rotating shaft rotationally connected to the top of the top cover, the second rotating shaft extends into the crystallizing tank, a spiral blade is installed on the side face of the second rotating shaft, and a first driving motor is installed at the top of the top cover. The first driving motor can drive the spiral blade to rotate, a solution at the bottom of the crystallizing tank is conveyed to the top of the crystallizing tank, meanwhile, the first rotating shaft can rotate along with the second rotating shaft under the action of the first gear and the second gear, and then the stirring blade stirs the solution in the crystallizing tank; therefore, the solution is uniformly cooled, and the crystallization effect is improved.